Type of TKI is associated with increased risk for cardiovascular and arteriothrombotic events.
The percentage of stromal TILs in the tumor environment was associated with improved disease-free and overall survival.
Neither a patient's CPY2D6 status nor endoxifen concentration affected relapse-free survival.
Inactivated influenza vaccine does not provoke untoward immune reactions in these patients.
Beyond holding anticoagulation, adding vitamin K did not reduce mortality, bleeding, or thrombosis risks in nonbleeding patients with elevated INRs.
Childhood survivors who received radiotherapy had a 30-fold increase in the incidence of basal cell carcinoma.
The combination failed to improve survival versus observation.
Sutimlimab, an anti-C1s antibody, was well tolerated and rapidly improved hemoglobin.
Cancer patients had significantly increased risk for arterial thrombosis in the year before cancer diagnosis.
Highlights of the latest GI cancer trials
Prof. Dr. med. Christoph Rochlitz
E-Mail: E-Mail anzeigen
In der vorliegenden Ausgabe von NEJM Journal Watch möchte ich Ihnen gerne wieder einige rezent publizierte Studien aus dem Bereich Onkologie/Hämatologie näherbringen.
The use of rituximab following consolidation therapy and autologous stem cell transplantation significantly improved patient outcomes.
Short-term reductions in agitation were helpful, but other components of delirium need further study.
Adding durvalumab to standard therapy significantly improved outcomes, but longer follow-up is required.
Long-term results confirm that survival is noninferior with sentinel versus axillary dissection.
More intense preoperative chemotherapy fails to improve survival.
The anti-PD-1 agent nivolumab was active in biomarker-defined patients with microsatellite instability-high or DNA mismatch repair-deficient disease.
Women's Health Initiative randomized trial findings suggest lowering dietary fat also lowers mortality after breast cancer.
Treatment was effective for 70% of hemorrhages associated with apixaban or rivaroxaban.
From 1990 through 2013, the percentage of patients with non–small-cell lung cancer who never smoked rose from 8.0% to 14.9%.
Palbociclib demonstrated activity in early-stage disease resistant to endocrine therapy, but prolonged exposure may be required.